3
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
5
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Celgene, a wholly owned subsidiary of Bristol-Myers Squibb is a company with 3 orphan drug designations across 5 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adult hepatocellular carcinoma | 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride | Des.TrialAppr. |
| diffuse large B-cell lymphoma | 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride | Des.TrialAppr. |
| follicular lymphoma | avadomide | Des.TrialAppr. |
| hepatocellular carcinoma | 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride | Des.TrialAppr. |
| pediatric hepatocellular carcinoma | 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
34
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
34
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
0
affecting portfolio